Plantar WartPhase 3NCT07830979
Hydrogen Peroxide 40% Versus Salicylic Acid 40% for Plantar Warts
A Phase 3 study testing Hydrogen Peroxide 40% and Salicylic Acid 40% in people with Plantar Wart, run by Assiut University.
Trial summary
This randomized controlled trial aims to compare the efficacy and safety of topical hydrogen peroxide 40 percent versus topical salicylic acid 40 percent in the treatment of plantar warts. Read more about this study
- Who is it for?
- Ages 12 years and older
- Conditions the study is for
- Plantar Wart
- What is being tested?
- Hydrogen Peroxide 40% and Salicylic Acid 40%
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 70 participants
- Where
- No sites listed yet
- Study dates
- 20 Sep 2026to 20 Feb 2028
- Phase
- Phase 3
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 12 years and older
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Age greater than or equal to 12 years of both sexes
- Clinically diagnosed plantar wart or warts
- Wart duration at least 2 weeks prior to enrollment
- Willing and able to give written informed consent or parental consent for minors
- Able to attend follow-up visits and comply with home-application protocol
Who cannot join
- Pregnant or lactating women
- Immunocompromised patients including HIV infection organ transplant recipients or on immunosuppressive therapy
- Diabetic patients with peripheral neuropathy or peripheral arterial disease
- Known hypersensitivity to hydrogen peroxide or salicylic acid
- Received any topical or systemic wart treatment within preceding 4 weeks
- Clinically atypical lesions raising suspicion of malignancy
- Active local skin infection or open wound at treatment site
- Unable or unwilling to complete follow-up schedule
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Topical Hydrogen Peroxide 40% Versus Salicylic Acid 40% in the Treatment of Plantar Warts: A Randomized Controlled Trial
This randomized controlled trial aims to compare the efficacy and safety of topical hydrogen peroxide 40 percent versus topical salicylic acid 40 percent in the treatment of plantar warts.
Read the detailed description
Plantar warts are common benign lesions caused by human papillomavirus on weight-bearing areas causing pain and functional impairment. This is a randomized parallel assignment study conducted at the Outpatient Dermatology Clinic Assiut University Hospital. Eligible patients with clinically diagnosed plantar warts will be randomized in 1 to 1 ratio to topical hydrogen peroxide 40 percent applied once weekly by physician or topical salicylic acid 40 percent self-applied once daily. Treatment duration 12 weeks with assessments every 2 weeks including measurement size photographs clearance status adverse effects compliance and satisfaction.
- Conditions
- Plantar Wart
- Being tested
- Hydrogen Peroxide 40%, Salicylic Acid 40%
- Keywords
- Hydrogen peroxide, Salicylic acid, Plantar warts, Topical treatment, HPV
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Hydrogen Peroxide 40%Drug
Topical hydrogen peroxide 40 percent w/w solution in opaque light-protected applicator bottle applied once weekly for up to 12 weeks
Salicylic Acid 40%Drug
Topical salicylic acid 40 percent w/w preparation applied once daily for up to 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| Topical Hydrogen Peroxide 40% | Experimental | Stabilized topical hydrogen peroxide 40 percent w/w applied directly onto wart surface using single-use wooden-tipped applicator avoiding surrounding skin once weekly by physician for 12 weeks or until complete clearance after soaking foot 5 to 10 minutes and gentle debridement Receives: Drug: Hydrogen Peroxide 40% |
| Topical Salicylic Acid 40% | Active comparator | Commercially available salicylic acid 40 percent w/w as paint or plaster self-applied once daily onto wart surface with protection of surrounding skin with petrolatum for 12 weeks after soaking and gentle paring Receives: Drug: Salicylic Acid 40% |
What is being measured
The primary outcome is the main question the study is designed to answer.
Number of participants with complete clinical clearance
Number of participants with complete clinical clearance defined as complete disappearance of plantar wart and restoration of normal skin markings
Measured: At 12 weeks
Secondary outcomes (6)
Time to complete clearance
Time in weeks from treatment start to complete clinical clearance
Measured: Up to 12 weeks
Change in wart surface area
Change in wart surface area in square millimeters measured in two perpendicular diameters using digital caliper from baseline
Measured: From baseline to 12 weeks
Treatment-related pain score
Pain score assessed using 0 to 10 Visual Analogue Scale with 0 indicating no pain and 10 indicating worst pain with higher scores indicating worse pain
Measured: Up to 12 weeks
Number of participants with local adverse effects
Number of participants who develop local adverse effects including blistering hyperpigmentation scarring or secondary infection
Measured: Up to 12 weeks
Patient satisfaction score
Patient satisfaction assessed using 0 to 10 satisfaction scale with higher scores indicating greater satisfaction
Measured: At 12 weeks
Number of participants with recurrence
Number of participants with recurrence of plantar warts after initial complete clearance
Measured: Up to 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Sep 2026
- Study start20 Sep 2026 (estimated)
- Primary completion20 Sep 2027 (estimated)
- Study completion20 Feb 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Plantar WartStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 70 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mohamed Ahmed Abdelrady Mahmoud, Assiut University
- Investigators
- Saher A Moez, prof, Study chair, Dermatology Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07830979
- Sponsor's protocol ID
- Plantar-Warts-H2O2-SA-Assiut-2
- Status last verified
- Sep 2026
- First submitted
- 15 Sep 2026
- Last updated
- 22 Sep 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 22 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Topical Hydrogen Peroxide 40% Versus Salicylic Acid 40% in the Treatment of Plantar Warts: A Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT07830979
- Acronym / sponsor ID
- Plantar-Warts-H2O2-SA-Assiut-2
- Conditions
- Plantar Wart
- Keywords
- Hydrogen peroxide, Salicylic acid, Plantar warts, Topical treatment, HPV
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 70 participants (estimated)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 20 Sep 2026 (estimated)
- Primary completion
- 20 Sep 2027 (estimated)
- Study completion
- 20 Feb 2028 (estimated)
- First posted
- 21 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This randomized controlled trial aims to compare the efficacy and safety of topical hydrogen peroxide 40 percent versus topical salicylic acid 40 percent in the treatment of plantar warts.
Detailed description
Plantar warts are common benign lesions caused by human papillomavirus on weight-bearing areas causing pain and functional impairment. This is a randomized parallel assignment study conducted at the Outpatient Dermatology Clinic Assiut University Hospital. Eligible patients with clinically diagnosed plantar warts will be randomized in 1 to 1 ratio to topical hydrogen peroxide 40 percent applied once weekly by physician or topical salicylic acid 40 percent self-applied once daily. Treatment duration 12 weeks with assessments every 2 weeks including measurement size photographs clearance status adverse effects compliance and satisfaction.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Topical Hydrogen Peroxide 40% | Experimental | Drug: Hydrogen Peroxide 40%Stabilized topical hydrogen peroxide 40 percent w/w applied directly onto wart surface using single-use wooden-tipped applicator avoiding surrounding skin once weekly by physician for 12 weeks or until complete clearance after soaking foot 5 to 10 minutes and gentle debridement |
| Topical Salicylic Acid 40% | Active comparator | Drug: Salicylic Acid 40%Commercially available salicylic acid 40 percent w/w as paint or plaster self-applied once daily onto wart surface with protection of surrounding skin with petrolatum for 12 weeks after soaking and gentle paring |
Who may qualify
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (5 listed)
- Age greater than or equal to 12 years of both sexes
- Clinically diagnosed plantar wart or warts
- Wart duration at least 2 weeks prior to enrollment
- Willing and able to give written informed consent or parental consent for minors
- Able to attend follow-up visits and comply with home-application protocol
Key exclusion criteria (8 listed)
- Pregnant or lactating women
- Immunocompromised patients including HIV infection organ transplant recipients or on immunosuppressive therapy
- Diabetic patients with peripheral neuropathy or peripheral arterial disease
- Known hypersensitivity to hydrogen peroxide or salicylic acid
- Received any topical or systemic wart treatment within preceding 4 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Hydrogen Peroxide 40%Topical hydrogen peroxide 40 percent w/w solution in opaque light-protected applicator bottle applied once weekly for up to 12 weeks | Drug | Topical Hydrogen Peroxide 40% |
| Salicylic Acid 40%Topical salicylic acid 40 percent w/w preparation applied once daily for up to 12 weeks | Drug | Topical Salicylic Acid 40% |
Primary outcome
Number of participants with complete clinical clearance
Time frame: At 12 weeks
Number of participants with complete clinical clearance defined as complete disappearance of plantar wart and restoration of normal skin markings
6 secondary outcomes
Time to complete clearance
Time frame: Up to 12 weeks
Change in wart surface area
Time frame: From baseline to 12 weeks
Treatment-related pain score
Time frame: Up to 12 weeks
Number of participants with local adverse effects
Time frame: Up to 12 weeks
Patient satisfaction score
Time frame: At 12 weeks
Number of participants with recurrence
Time frame: Up to 12 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Sep 2026.
Related trials for Plantar Wart
Recruiting
Liquid Nitrogen Cryotherapy Versus CO₂ Laser for Palmoplantar Warts
Palmoplantar Warts
Not yet recruitingPhase 3
Intralesional Acyclovir Versus Intralesional Zinc Sulphate in the Treatment of Plantar Warts
Warts, Plantar Warts
RecruitingPhase 4
Randomized, Placebo-controlled, Double Blind Study to Evaluate the Efficacy of 2LVERU®JUNIOR and 2LVERU® on the Treatment of Warts
Common Wart, Flat Wart
RecruitingPhase 4
Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
Viral Wart, Plantar Wart
Active, not recruitingPhase 4
A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts
Plantar Wart
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Saher A Moez, prof study chair
Dermatology Department, Assiut University Hospitals
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Hydrogen Peroxide 40% and Salicylic Acid 40% in people with Plantar Wart, run by Assiut University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Mohamed A Abdel rady, Resident (01024907721, mohamedradybalela199769@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Number of participants with complete clinical clearance (time frame: At 12 weeks). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Sep 2026.